Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.

The Journal of rheumatology - 1 Mar 2017

Moghadam-Kia Siamak, Oddis Chester V, Sato Shinji, Kuwana Masataka, Aggarwal Rohit

Abstract excerpt

OBJECTIVE: To determine the clinical features associated with the antimelanoma differentiation-associated gene 5 antibody (anti-MDA5) in US patients with clinically amyopathic dermatomyositis (CADM) and classic DM. METHODS: Patients with CADM were consecutively selected from the University of Pittsburgh Myositis Database from 1985 to 2013. CADM was defined by a typical DM rash without objective muscle weakness...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoantibodies
Share to Dermatomyositis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease Progression

Share to Interferon-Induced Helicase, IFIH1

Share to Phenotype

Share to Symptom Assessment

Source

Identifiers

PMID: 28089977
DOI: 10.3899/jrheum.160682

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.PMID 28089977Read ↗

Anti-melanoma differentiation-associated gene 5 (Anti-MDA5) antibody dermatomyositis: Clinical features and outcomes in a racially diverse patient cohortSemantic proximity Read ↗

Anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses.Semantic proximity Read ↗

Case Report: Anti-MDA-5 dermatomyositis in a resource-limited settingSemantic proximity Read ↗

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.Semantic proximity Read ↗

Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients.Semantic proximity Read ↗

A retrospective study for clinical characteristics of 293 patients with dermatomyositis.Semantic proximity Read ↗

Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis.Semantic proximity Read ↗

Pathogenesis of Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis: A Concise Review With an Emphasis on Type I Interferon SystemSemantic proximity Read ↗

Clinical phenotype and prognostic determinants of spontaneous pneumomediastinum in anti-MDA5 antibody-positive dermatomyositis.Semantic proximity Read ↗

Identification of Three Different Phenotypes in Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis Patients: Implications for Prediction of Rapidly Progressive Interstitial Lung Disease.Semantic proximity Read ↗

Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicrySemantic proximity Read ↗

Analysis of anti-melanoma differentiation-associated gene 5 antibody in Hong Kong Chinese patients with idiopathic inflammatory myopathies: diagnostic utility and clinical correlations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.